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ABSTRACT 24 
Introduction/Aims: Intestinal production of endocannabinoid and oleoylethanolamide (OEA) is 25 
impaired in high-fat diet/obese rodents, leading to reduced satiety. Such diets also alter the 26 
intestinal microbiome in association with enhanced intestinal permeability and inflammation, 27 
however little is known of these effects in humans. This study aimed to: (i) evaluate effects of lipid 28 
on plasma anandamide (AEA), 2-arachidonyl-sn-glycerol (2-AG) and OEA in humans, and (ii) 29 
examine relationships with intestinal permeability, inflammation markers and incretin hormone 30 
secretion.  31 
Methods: 20 lean, 18 overweight and 19 obese participants underwent intraduodenal Intralipid® 32 
infusion (2 kcal/min) with collection of endoscopic duodenal biopsies and blood. Plasma AEA, 33 
2-AG, and OEA (HPLC/tandem mass spectrometry), tumour necrosis factor-α (TNF-α), 34 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) 35 
(multiplex), and duodenal expression of occludin, zona-occludin-1 (ZO-1), intestinal-alkaline-36 
phosphatase (IAP), and toll-like receptor-4 (TLR4) (RT-PCR), were assessed.  37 
Results: Fasting plasma AEA was increased in obese, compared with lean and overweight 38 
(P<0.05), with no effect of BMI group or ID lipid infusion on plasma 2-AG or OEA. Duodenal 39 
expression of IAP and ZO-1 was reduced in obese, compared with lean (P<0.05), and these levels 40 
related negatively to plasma AEA (P<0.05).  The iAUC for AEA was positively related to iAUC 41 
GIP (r=0.384, P=0.005).  42 
Conclusions: Obese individuals have increased plasma AEA and decreased duodenal expression 43 
of ZO-1 and IAP, in comparison to lean and overweight. The relationships between plasma AEA 44 
with duodenal ZO-1 and IAP, and GIP, suggest that altered endocannabinoid signalling may 45 
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contribute to changes in intestinal permeability, inflammation and incretin release in human 46 
obesity. 47 
 48 
Keywords: Intestinal fat sensors, anandamide, 2-arachidonylglycerol, n-acylethanolamines, tight 49 
junction proteins, inflammation.  50 
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INTRODUCTION  51 
Obesity is associated with chronic low-grade inflammation and metabolic disturbances, including 52 
insulin resistance and type 2 diabetes. One of the major drivers of the obesity epidemic is the 53 
consumption of an energy-dense high-fat diet, which promotes hyperphagia secondary to 54 
attenuation of the gut-brain signalling mechanisms involved in the control of food intake (24). In 55 
rodents, high-fat diet-induced hyperphagia is driven by alterations in the composition of the gut 56 
microbiota with consequent development of low-grade inflammation in the gastrointestinal tract. 57 
This is evidenced by increased expression of toll-like receptor 4 (TLR-4, the receptor for the 58 
microbial toxin, lipopolysaccharide (LPS or endotoxin)), in the ileum (11), increased systemic 59 
levels of LPS and proinflammatory cytokines (3), and altered intestinal permeability characterised 60 
by decreased intestinal expression and localisation of tight junction proteins, including zona-61 
occludin 1 (ZO-1) and occludin (4). Furthermore, the intestinal expression of intestinal alkaline 62 
phosphatase (IAP), an enzyme that inactivates LPS, is decreased by a high-fat diet in obesity-63 
prone, but not obesity-resistant, rodents (11). Recent studies have also highlighted an important 64 
role of interactions between the gut microbiota and the endocannabinoid system in the regulation 65 
of energy homeostasis (29).   66 
 67 
The endocannabinoids, 2-arachidonyl-sn-glycerol (2-AG) and anandamide (AEA), are lipid-68 
derived mediators that are involved in the control of food intake (1, 13). 2-AG and AEA stimulate 69 
food intake by activating cannabinoid-1 (CB1) receptors (16). In the small intestine of rodents, 2-70 
AG and AEA concentrations increase with fasting (14, 21) and upon oral sensing of dietary fats 71 
(13), and both 2-AG and AEA decrease with refeeding (21). Intestinal levels of endocannabinoids 72 
are altered in obesity, for example, obese Zucker rats exhibit higher duodenal levels of 2-AG and 73 
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AEA than wild-type rats following both food deprivation and refeeding, while in high-fat diet 74 
induced obese rats, duodenal 2-AG is higher, but AEA lower, than in control rats fed a standard 75 
laboratory diet (21). In Western diet (high-fat, high-sucrose)-induced obese mice, both 2-AG and 76 
AEA are increased (1). While studies are inconsistent, human obesity is generally associated with 77 
increased concentrations of endocannabinoids in plasma and adipose tissues, and most commonly 78 
elevated 2-AG, but not AEA, correlates with BMI and waist circumference (2, 7, 12). While now 79 
withdrawn from the market due to adverse psychological effects, the CB1 receptor antagonist 80 
Rimonabant promoted weight loss in obese humans (23).  Interest in the endocannabinoid system 81 
as a target for obesity therapy has re-emerged since rodent studies demonstrated that obesity-82 
associated changes in the gut microbiota activated the intestinal endocannabinoid system (via LPS) 83 
to increase gut permeability, which further enhanced plasma LPS levels and peripheral 84 
inflammation (5, 29). Studies examining the relationships between intestinal endocannabinoids, 85 
intestinal permeability and inflammation are lacking in humans, although a recent study using 86 
human colonic explants from patients with inflammatory bowel disease has reported that 87 
cannabidiol and palmitoylethanolamine exert anti-inflammatory effects (8).  88 
 89 
Endocannabinoids may also determine the secretion of the incretin hormones, glucose-dependent 90 
insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). CB1 receptors are expressed on 91 
enteroendocrine K- and L-cells in rodents (19, 28), and activation of the CB1 receptor by AEA 92 
prior to an oral glucose tolerance test inhibits GIP secretion in rodents (28). In contrast, in humans, 93 
acute administration of the CB1 receptor agonist, nabilone, enhances fasting plasma GIP by ~80%, 94 
has no effect on glucose-mediated GIP release, but decreases the GLP-1 response to oral glucose 95 
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(6).  Therefore, while it has not been directly evaluated, changes in incretin levels observed in 96 
obesity (35) may arise due to altered endocannabinoid levels.  97 
 98 
Endocannabinoid-related molecules, such as the fatty acid-derived n-acylethanolamines, and in 99 
particular, OEA, have also been shown to play a role in energy homeostasis, where they reduce 100 
energy intake (by prolonging the inter-meal interval and reducing meal frequency) via activation 101 
of the nuclear receptor, peroxisome-proliferator-activated receptor- (PPAR-) (17, 25, 31).  OEA 102 
is also an endogenous ligand for the fatty acid sensing receptor, GPR119, which stimulates GLP-1 103 
secretion (22, 30).  Whether OEA levels are altered in human obesity is currently unclear.  104 
 105 
We recently characterised the effects of intraduodenal lipid infusion on the duodenal expression 106 
of fat sensing molecules in lean, overweight and obese humans. We reported that human obesity 107 
was associated with altered capacity for the sensing of dietary fat, including decreased duodenal 108 
expression of free fatty acid receptors (FFAR) 1 and 4, and increased expression of cluster of 109 
differentiation 36 (CD36) (9, 10). Using plasma samples and duodenal biopsies collected in these 110 
studies, the aim of the current investigation was to (i) evaluate effects of intraduodenal lipid 111 
infusion on plasma levels of AEA, 2-AG and OEA in humans, and (ii) examine relationships 112 
between plasma concentrations of endocannabinoid related molecules with BMI, intestinal 113 
permeability and inflammation markers, and incretin hormone secretion.   114 
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MATERIALS AND METHODS 115 
Participants 116 
20 lean (10 males, body mass index (BMI: 22±0.5 kg/m2, age: 28±2 years), 18 overweight (12 117 
males, BMI: 27±0.3 kg/m2, age: 32±3 years) and 19 obese (12 males, BMI: 35±1 kg/m2, age: 30±2 118 
years) participants were enrolled in the study. Participant demographics have been published 119 
previously (9, 10). In brief, all participants were weight-stable for at least 3 months prior to 120 
inclusion in the study and reported no gastrointestinal (GI) symptoms, had no prior GI surgery, did 121 
not take medications or supplements known to affect GI motility or appetite (including fish oil), 122 
consumed <20 g of alcohol per week, and were non-smokers. The study protocol was approved by 123 
the Royal Adelaide Hospital Research Ethics Committee and carried out in accordance with the 124 
Declaration of Helsinki. Each participant provided written informed consent prior to inclusion in 125 
the study. The trial was registered with the Australia and New Zealand Clinical Trial Registry 126 
(www.anzctr.org.au trial number: ACTRN12612000376842). 127 
 128 
Study design and protocol  129 
Part A: Endoscopy and collection of duodenal mucosal biopsies 130 
Participants attended the Department of Gastroenterology and Hepatology, Royal Adelaide 131 
Hospital, at 0830 h following a standardized evening meal (400 g beef lasagne (2479 kJ, 20 g fat, 132 
20 g protein, 80 g carbohydrate), McCain Foods, Wendouree, Victoria, Australia) and an overnight 133 
fast of 12 h from solids and 10 h from liquids. The protocol for endoscopic collection of mucosal 134 
biopsies has been described previously (9).  Briefly, a small diameter video endoscope was passed 135 
through the nose into the second part of the duodenum and once positioned, 2 duodenal biopsies 136 
were collected using standard endoscopic biopsy forceps and placed immediately in Allprotect® 137 
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Tissue Reagent (Qiagen, Australia). An intravenous cannula was inserted into a forearm vein and 138 
a baseline blood sample (10 ml) was collected (t = 0 min). Following this, an intraduodenal 139 
infusion of 10% Intralipid® (Fresenius Kabi AB, China; 2 kcal/min, 109 ml/hr) commenced via 140 
the endoscope infusion channel for 30 min. Blood samples, for analysis of plasma TNF-α 141 
concentrations, were collected at t = 10, 20 and 30 min, and placed in ice-chilled EDTA-treated 142 
and serum tubes, as described previously (9). After the infusion (t = 30 min), two additional 143 
duodenal biopsies were collected.  144 
 145 
Part B: Effect of intraduodenal lipid infusion on plasma concentrations of endocannabinoids and 146 
incretins 147 
Participants attended the Discipline of Medicine at 0830 h following a standardized evening meal 148 
and overnight fast, as described above. Anesthetic spray and gel was administered into the nasal 149 
cavity (as above) prior to insertion of a small-diameter (3.5 mm) catheter (Dentsleeve 150 
International, Mui Scientific), which was allowed to pass via peristalsis through the pylorus into 151 
the second part of the duodenum. Accurate positioning of the catheter across the pylorus was 152 
achieved by monitoring the transmucosal potential difference using a monitoring electrode (Red 153 
Dot, 3M Healthcare) placed on the forearm as a reference (20). Once positioned, an intravenous 154 
cannula was inserted into a forearm vein and a baseline blood sample (10 ml) was collected (t = 0 155 
min). Intraduodenal infusion of 10% Intralipid® then commenced at a rate of 2 kcal/min for 120 156 
min (t = 0 - 120 min), during which blood samples were collected every 15 min and placed in ice-157 
chilled EDTA-treated and serum tubes, as described previously (9). 158 
 159 
 160 
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Measurements 161 
Analysis of AEA, OEA and 2-AG levels in plasma 162 
Plasma samples collected at t = 0, 30, 60 and 120 min were analysed. Lipid extraction and analysis 163 
were performed as previously described (1). Plasma (0.5 mL) was added to 1.0 mL of methanol 164 
solution containing the internal standards, [2H5]- 2-AG, [
2H4]-AEA, and [
2H4]-OEA (Cayman 165 
Chemical, Ann Arbor, MI, USA). Lipids were extracted with chloroform (2 mL) and washed with 166 
0.9 % saline (0.5 mL). Organic phases were collected and separated by open-bed silica gel column 167 
chromatography. The eluate was gently dried under a N2 stream (99.998% pure) and resuspended 168 
in 0.1 mL of methanol:chloroform (9:1), with 1 μL injected for ultra-performance liquid 169 
chromatography/tandem mass spectrometry (UPLC/MS/MS) analysis. 170 
 171 
Data were collected using an Acquity I Class UPLC system coupled to a Xevo TQ-S Mass 172 
Spectrometer (Waters, Milford, MA, USA) with accompanying electrospray ionization (ESI) 173 
interface. Lipids were separated on an Acquity UPLC BEH C18 column (2.1 x 50 mm i.d., 1.7µm, 174 
Waters) with inline Acquity guard column (UPLC BEH C18 VanGuard Pre-column; 2.1 x 5 mm 175 
i.d., 1.7µm, Waters), and eluted by a gradient of methanol in water (0.25% acetic acid, 5mM 176 
ammonium acetate) according to the following gradient at a flow rate of 0.4 mL per min: 80% 177 
methanol 0.5 min, 80% - 100% methanol 0.5-2.5 min, 100% methanol 2.5-3 min, 100% - 80% 178 
methanol 3-3.1 min). Column temperature was maintained at 40 °C, and samples were maintained 179 
in the sample manager at 10 °C. Argon (99.998%) was used as collision gas. MS detection was in 180 
positive ion mode and capillary voltage set at 0.1 kV. Cone voltage and collision energy as follows, 181 
respectively: 2-AG = 30v, 12v; [2H5] 2-= 25v, 44v; AEA = 30v, 14v; [
2H4] AEA = 26v, 16v; OEA 182 
= 28v, 16v; [2H4]- OEA = 48v. 14v. Lipids were quantified using a stable isotope dilution method 183 
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detecting protonated adducts of the molecular ions [M+H]+ in the multiple reaction monitoring 184 
(MRM) mode. Acyl migration from 2-arachidonylglycerol to 1-arachidonylglycerol is known to 185 
occur (32), thus all reported values for 2-AG represent the sum of 2-AG and 1-AG. Tissue 186 
processing and LCMS analysis from an individual experiment occurred independently of other 187 
experiments. Extracted ion chromatograms were used to quantify 2-AG (m/z = 379.3>287.3), AEA 188 
(m/z = 348.3>62.0), and OEA (m/z = 326.4 > 62.1), and [2H5]2-AG (m/z = 384.3 > 93.4), [
2H4]-189 
AEA (m/z = 352.3>66.1), and [2H4]-OEA (m/z = 330.4 > 66.0), which were used as internal 190 
standards.  191 
 192 
RNA extraction 193 
Frozen duodenal biopsies were disrupted using a bead-based tissue homogeniser (TissueLyser LT, 194 
Qiagen) and homogenised through Qiashredder columns (Qiagen). Total cellular RNA was 195 
isolated using the PureLinkTM MicroKit (Invitrogen, Thermo Fisher Scientific), which included an 196 
on-column DNase digestion, as per manufacturer’s instructions. RNA quantity was determined 197 
using a NanodropTM Lite Spectrophotometer (Thermo Fisher Scientific) and purity assessed using 198 
A260/A280 ratio.  199 
 200 
Quantification of duodenal gene expression by relative RT-PCR 201 
Real-time RT-PCR was performed using the 7500 fast Real-Time PCR system (Applied 202 
Biosystems, Thermo Fisher Scientific). Taqman® primers (Life Technologies, Thermo Fisher 203 
Scientific) were used to determine the expression of TLR4 (Hs00152939_m1), IAP (alkaline 204 
phosphatase-1) (ALP1, Hs00357579_g1), occludin (OCLN, Hs00170162_m1), and ZO-1 (tight 205 
junction protein-1) (TJP1, Hs01551861_m1) relative to expression of the housekeeper beta-2 206 
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microglobulin (β2M) (Hs00984230_m1). All targets were assessed in triplicate, according to 207 
manufacturer’s instructions. 208 
 209 
Plasma tumour necrosis factor-α (TNF-α) and incretin hormone concentrations 210 
Multiplex assays were used to determine plasma TNF-α concentrations (pg/mL) (t = 0, 10, 20, 30 211 
min) (Milliplex® MAP Human Cytokine/Chemokine Magnetic Bead Panel, HCYTOMAG-60K), 212 
and total GLP-1 and GIP concentrations (both pg/ml) (t = 0, 15, 30, 60, 90, 120 min) (Milliplex 213 
MAP Human Metabolic Hormone Magnetic Bead Panel, HMHEMAG-34K; Millipore 214 
Corporation, Temecula, CA, USA) using the Bio-plex® MAGPIXTM Multiplex Reader (Luminex®, 215 
Millipore Corporation) and xPONENT® software (Luminex®, Millipore Corporation, version 4.2) 216 
according to manufacturer’s instructions. There was negligible antibody cross-reactivity. Intra-217 
assay coefficients of variation (CVs) were ≤ 10%, and inter-assay CVs were ≤ 15% for all analytes. 218 
The minimum detection limits were for TNF-α: 0.7 pg/mL, GLP-1: 2.5 pg/ml, GIP: 0.6 pg/ml.   219 
 220 
Data and statistical analyses 221 
Statistical analysis was performed using SPSS® software (SPSS Inc, IBM®, version 24), and all 222 
graphs were generated using GraphPad Prism 7 (GraphPad Software Inc). One-way ANOVA with 223 
post-hoc Bonferroni testing was used to compare values for all variables across BMI group (i.e. 224 
lean, overweight, obese) and time. Post-hoc paired comparisons, corrected for multiple 225 
comparisons using Bonferroni’s correction, were performed if ANOVAs revealed significant 226 
effects.  Relationships between variables were determined by correlation, with Pearson’s r values 227 
presented.  Incretin hormone, AEA, 2-AG and OEA data were expressed as incremental area under 228 
the curve (iAUC) (calculated using the trapezoidal rule from t = 0 min to 120 min (or t = 0 – 30 229 
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min for TNF-α)). This iAUC value was divided by the time of last measurement to obtain a final 230 
weighted average (AUC) to account for rare times when samples could not be collected (e.g. 231 
bathroom breaks) or data could not be obtained from the assays (10). Data are expressed as mean 232 
± standard error of the mean (SEM), with statistical significance accepted at P < 0.05.  233 
234 
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RESULTS 235 
Plasma 2-AG, AEA and OEA concentrations 236 
There was no significant difference between BMI groups, or effect of lipid infusion, on plasma 2-237 
AG concentrations (Figure 1A).  There was a significant effect of BMI group (P=0.003), but not 238 
lipid infusion, on plasma AEA concentrations (Figure 1B). Plasma AEA was higher in obese 239 
compared with both lean (P=0.005) and overweight (P=0.017), with no difference between lean 240 
and overweight groups. There was no significant difference between BMI groups, or effect of lipid 241 
infusion, on plasma OEA concentrations (Figure 1C).  242 
 243 
Duodenal expression of TLR4, IAP, occludin, and ZO-1 244 
Baseline duodenal expression of IAP (P=0.018) and ZO-1 (P=0.002) was significantly different 245 
across BMI groups, with a trend for difference evident for TLR-4 (P=0.08) and occludin (P=0.08) 246 
(Figure 2). Baseline IAP expression was significantly lower in obese compared with lean 247 
(P<0.05), with no difference between lean and overweight, or obese and overweight groups. 248 
Baseline ZO-1 expression was significantly lower in obese compared with lean (P=0.002), and in 249 
overweight compared with lean (P=0.029), with no difference between overweight and obese 250 
groups. There was no effect of intraduodenal lipid on duodenal expression of TLR-4, IAP, occludin 251 
or ZO-1 (data not shown).   252 
 253 
Plasma TNF-α concentrations 254 
There was no significant difference between BMI groups (P=0.7), and no effect of lipid infusion 255 
(P=0.2) on plasma concentrations of TNF-α (Figure 3).  256 
 257 
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Plasma incretin hormone concentrations 258 
Data are available in the publication from Cvijanovic et al (10).  259 
 260 
Relationships between variables 261 
Plasma AEA concentrations at baseline were positively related to BMI (r=0.34, P=0.014). Baseline 262 
expression of IAP (r=-0.329, P=0.014), occludin (r=-0.28, P=0.038) and ZO-1 (r=-0.395, P=0.003) 263 
was negatively related to BMI. Intralipid-evoked AEA concentrations (plasma iAUC) were 264 
negatively related to baseline TLR4 (r=-0.283, P=0.04), IAP (r=-0.305, P=0.032), occludin (r=-265 
0.398, P=0.001) and ZO-1 expression (r=-0.445, P=0.001). Plasma TNF-α concentrations at 266 
baseline related positively to expression of IAP (r=0.401, P=0.002) and ZO-1 at baseline (r=0.256, 267 
P=0.05). Finally, Intralipid-evoked AEA was positively related to evoked GIP (iAUC, r=0.384, 268 
P=0.005), but not to evoked GLP-1. 269 
270 
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DISCUSSION 271 
We have demonstrated that fasting plasma levels of the endocannabinoid, AEA, but not 2-AG or 272 
the endocannabinoid-related OEA, were higher in obese, when compared with lean and overweight 273 
individuals. Obese individuals also had lower duodenal expression of ZO-1 and IAP, and a trend 274 
towards lower duodenal occludin and TLR4 expression at baseline. These changes were negatively 275 
related to plasma AEA concentrations, suggesting that altered endocannabinoid signalling may 276 
contribute to changes in intestinal permeability and inflammation in human obesity. Plasma AEA 277 
levels were also positively related to plasma GIP, adding support that the endocannabinoid system 278 
plays a significant role in mediating GIP secretion in humans. 279 
  280 
Our finding of increased plasma AEA in obesity is consistent with reports in animals and humans 281 
that document increased peripheral endocannabinoid levels in obesity (1, 12, 21, 26). While many 282 
studies report strong correlations between plasma 2-AG with body fat (2), we were not able to 283 
replicate these findings. Although mean levels of 2-AG were higher in obese, when compared with 284 
both lean and overweight individuals, the values were far more variable than those for AEA, and 285 
for this reason we believe our study may have been underpowered to detect such a correlation. 286 
Rodent studies indicate that changes in peripheral endocannabinoid concentrations are induced by 287 
a “Western” style high-fat diet (1), and that elevated endocannabinoid levels in plasma and jejunal 288 
mucosa act via peripheral CB1 receptors to promote hyperphagia (1). Mammals have an innate 289 
preference for dietary fats, and in sham fed rats, where food is tasted but does not enter the small 290 
intestine, corn oil, or emulsions containing oleic or linoleic acid, rapidly and markedly increase 291 
jejunal levels of 2-AG and AEA (13, 15). Moreover, CB1 receptor blockade abolishes effects of 292 
oral fat on sham feeding and preference for fat (15). Accordingly, changes in peripheral 293 
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endocannabinoid signalling in obesity may be important mediators of both fat preference and gut-294 
to-brain signalling mechanisms involved in the regulation of energy intake.  Acute intraduodenal 295 
infusion of lipid had no effect on plasma endocannabinoid levels in the current study. It is possible 296 
that the duration and/or load of lipid exposure was insufficient, or that oral stimulation of fatty-297 
acid sensing receptors (13), such as CD36 and GPR40 and 120, is required to elicit changes in 298 
peripheral endocannabinoid levels, and further studies are needed to address this question in 299 
humans.  300 
 301 
Duodenal expression of IAP and the tight-junction protein ZO-1 was reduced in obese compared 302 
to lean individuals, and there was a trend for reduced expression of TLR4 and occludin. These 303 
molecules are important markers of increased intestinal permeability and inflammation, that have 304 
been shown in animal studies to be altered secondary to high-fat diet and obesity-induced changes 305 
in the intestinal microbiome (11), associated with increased systemic levels of LPS, termed 306 
“metabolic endotoxemia” (2, 3). These data suggest that the observed changes in duodenal 307 
expression of IAP and ZO-1 in obese, compared to lean, are surrogate markers of an altered 308 
intestinal microbiome and enhanced intestinal permeability, however, this requires further direct 309 
investigation. Furthermore, the potential role of dietary fat intake remains to be elucidated.  In 310 
humans, acute ingestion of fat has been associated with an increase in circulating LPS (18), and 311 
increased intestinal permeability (assessed by lactulose/mannitol tests) in obese individuals (33). 312 
Not all studies show changes in intestinal permeability, despite evidence of increased local and 313 
systemic inflammation in obese individuals (34), which may reflect the relative insensitivity of the 314 
intestinal permeability tests based on detection of urinary markers in humans. In the present study, 315 
we identified a relationship between the duodenal expression of IAP and ZO-1 with plasma levels 316 
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of the pro-inflammatory cytokine, TNF-α, suggesting an important role for these molecules in 317 
mediating the chronic low-grade inflammation associated with obesity. 318 
 319 
We also found that lipid-evoked plasma AEA levels were negatively related to baseline duodenal 320 
expression of TLR4, IAP, occludin and ZO-1.  Rodent studies have provided evidence that the 321 
obesity-associated changes in the gut microbiota leads to activation of the endocannabinoid system 322 
(via LPS).  Administration of the CB1 receptor agonist, HU-210, to wild-type mice increased 323 
intestinal permeability, and decreased ZO-1 and occludin expression in vitro, in Caco-2 cells (29).  324 
Conversely, in obese mice, pharmacological blockade of the CB1 receptor restored the distribution 325 
and localisation of the tight-junction proteins ZO-1 and occludin, and decreased plasma LPS levels 326 
(5, 29).  Accordingly, in human obesity, altered plasma AEA may be an important mediator of the 327 
effects of obesity on intestinal permeability and inflammation. In rodents, alterations in the 328 
composition of the gut microbiota with consequent development of low-grade inflammation in the 329 
gastrointestinal tract, have been shown to be responsible for the development of hyperphagia and 330 
obesity (11). Further studies in humans are now required to understand the relationships between 331 
these changes in endocannabinoid system activity, intestinal permeability and food intake.  332 
 333 
Plasma AEA concentrations related positively to plasma GIP, but not GLP-1, concentrations. 334 
Recent studies have suggested a role of the endocannabinoid system in mediating the secretion of  335 
incretin hormones (6). As discussed, CB1 receptors are expressed on enteroendocrine K- and L-336 
cells in rodents (19, 28), and AEA inhibits the GIP response to oral glucose in rodents (28). In 337 
contrast, our data, and a recent study using acute administration of the CB1 receptor agonist, 338 
nabilone (6), provide evidence that AEA enhances GIP secretion in humans. The reasons for these 339 
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discrepancies are unclear, however, the endocannabinoid system is likely to play an influential role 340 
in mediating the GIP response to fat in humans.  341 
 342 
Plasma OEA concentrations did not differ between lean, overweight and obese humans during 343 
fasting, and did not change in response to duodenal fat infusion. In rodents, the presence of fat in 344 
the duodenum stimulates the small intestinal conversion of oleic acid, found commonly in the diet, 345 
to OEA (31). When administered exogenously to rodents, OEA reduces overall energy intake by 346 
prolonging the time interval between meals (31). Our infused lipid emulsion comprised ~19-30% 347 
oleic acid, which may have been insufficient to stimulate OEA mobilisation in the current study. 348 
Previous studies in humans have demonstrated a significant increase in plasma OEA 349 
concentrations in proportion to the oleic content of the ingested oil (30 g), which was associated 350 
with reduced subsequent energy intake (27). 351 
 352 
In conclusion, we have demonstrated increased plasma levels of AEA, but not 2-AG or OEA, in 353 
obese, compared to lean and overweight individuals. Obese individuals also displayed decreased 354 
fasting duodenal expression of ZO-1 and IAP. Plasma AEA concentrations were negatively related 355 
to duodenal expression of ZO-1 and IAP, and positively related to plasma GIP, suggesting that 356 
altered endocannabinoid signalling may contribute to changes in intestinal permeability, 357 
inflammation and GIP secretion in human obesity.  358 
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FIGURE LEGENDS 480 
Figure 1: Plasma 2-arachidonylglycerol (2-AG) (A), anandamide (AEA) (B), and 481 
oleoylethanolamide (OEA) (C) concentrations at fasting (0 min) and during intraduodenal infusion 482 
of Intralipid (2 kcal/min for 120 min) in lean (n= 20), overweight (n=18) and obese (n=19) 483 
individuals. There was no significant difference between BMI groups, or effect of lipid infusion, 484 
on plasma 2-AG (A) or OEA (C) concentrations.  Plasma AEA was higher in obese compared with 485 
both lean (P=0.005) and overweight (P=0.017), with no difference between lean and overweight 486 
groups. *P<0.05 vs. lean and overweight.   487 
Figure 2: Baseline duodenal expression of toll-like receptor-4 (TLR4) (A), intestinal alkaline 488 
phosphatase (IAP) (B), occludin (C), and zona-occludin 1 (ZO-1) (D) in lean (n=20), overweight 489 
(n=18) and obese (n=19) individuals. Baseline IAP expression (B) was significantly lower in obese 490 
compared with lean (P<0.05), with no difference between lean and overweight, or obese and 491 
overweight groups. Baseline ZO-1 expression (D) was significantly lower in obese compared with 492 
lean (P=0.002), and in overweight compared with lean (P=0.029), with no difference between 493 
overweight and obese groups. *P<0.05 obese vs. lean, #P<0.05 overweight vs. lean.  494 
Figure 3: Plasma tumour-necrosis factor-α (TNF-α) concentrations at fasting (0 min) and during 495 
intraduodenal infusion of Intralipid (2 kcal/min for 120 min) in lean (n=19), overweight (n=16) 496 
and obese individuals (n=17). There was no significant difference between BMI groups (P=0.7), 497 
and no effect of lipid infusion (P=0.2) on plasma concentrations of TNF-α. Sufficient plasma was 498 
not available for 1 lean, and 2 overweight and 2 obese individuals.  499 
 500 
 501 
